Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.
about
Alpha-, Delta- and PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination?Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the BlockPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseIsosteviol has beneficial effects on palmitate-induced α-cell dysfunction and gene expressionExercise resistance across the prediabetes phenotypes: Impact on insulin sensitivity and substrate metabolism.Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.Insulin and glucagon regulate pancreatic α-cell proliferationCharacterization of the expression, localization, and secretion of PANDER in alpha-cells.A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitus-syndrome X complex.Pancreatic surgery, not pancreatitis, is the primary cause of diabetes after acute fulminant pancreatitisMicroRNA-214 suppresses gluconeogenesis by targeting activating transcriptional factor 4Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.Hepatic TRAF2 regulates glucose metabolism through enhancing glucagon responses.Mice Deficient in Proglucagon-Derived Peptides Exhibit Glucose Intolerance on a High-Fat Diet but Are Resistant to Obesity.Novel Agents for the Treatment of Type 2 Diabetes.Pleiotropic effects of incretinsGlucagon as a target for the treatment of Type 2 diabetes.Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass?A computational systems analysis of factors regulating α cell glucagon secretion.Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides.HIF2α Is an Essential Molecular Brake for Postprandial Hepatic Glucagon Response Independent of Insulin Signaling.Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1.Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.Activation of the cAMP-PKA pathway Antagonizes Metformin Suppression of Hepatic Glucose Production.X-box binding protein 1 is essential for insulin regulation of pancreatic α-cell function.Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusBenefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia.Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein.Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Type 2 diabetes: an expanded view of pathophysiology and therapy.Choosing a gliptin.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Validation of a metabolite panel for early diagnosis of type 2 diabetes.Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.β-Cell dysfunction in diabetes: a crisis of identity?Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Regulation of hepatic glucose metabolism in health and disease.Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells.
P2860
Q26799155-15D995DF-9CA2-4E79-8C76-731EEE3FD468Q26825393-B09204D0-7A6E-44FF-BE1F-5AFF86F2F41DQ27027920-9883D64B-8D9F-4F6C-A9EC-CAF1B539DE17Q28481674-9D36F252-DCEB-4D96-9181-4DE990DEBE80Q30276925-0E6145F9-0104-4B41-A17F-8E5B4491BF89Q30395512-F2507C07-DA8C-4D29-A9C6-C5B237F500D0Q33808713-5395002C-DB3A-4AA0-BA5C-7B3795FFF377Q34015340-EBAD5A46-6339-4CA9-9CB6-A127E605BC54Q34193110-4CAE0AD0-B40D-449E-B047-5833C527332FQ34395503-E12C8035-5A8C-4194-BD42-7DEBB36B50B7Q35221535-94B6C9B2-0C26-4341-B356-57D6761B3114Q35762651-FF7CF83A-9130-48DE-ADF2-06E28AE77543Q35766938-22119E03-190F-4110-B0D7-011C163AF7FFQ35778163-ADFA2D6C-0D1B-47E2-8784-57F4ED1C4AAEQ35910421-3A727542-BB03-41D4-8C06-AE2D09E2FE55Q35968092-33CD3AA5-98F1-41EB-A847-9D5C7A55B48EQ36158732-8A92F182-B187-4FD0-8FA1-D57048EEE021Q36163431-97F689C9-0ED9-4BBF-98B6-C96C6D6D2DB8Q36394674-9BBF32B0-C5DB-4C00-9FC4-FD2DF9E282C9Q36560559-1514DAF0-1B5E-4C44-ABC9-508C77ED2002Q36669733-477BA30F-DB4C-4C2B-B068-B52BFE18E4E7Q36715658-BB4E0CBF-00A4-43C1-8E79-F773C9968380Q36842541-E6A436A2-3BCC-435B-AC40-76C6567794C0Q36898203-487BCE95-0E0D-4646-BB89-453065FFBC31Q37015048-505E5910-E8BF-48A6-9833-9053C63E92DEQ37141727-B22F2C7D-DDE0-4B76-8D3F-077B5652BC84Q37360316-8694FB82-4749-44EA-A389-563D3E908EE0Q37376587-738D381F-A54B-408D-9289-D033B2C26588Q37417220-9C8F9810-0A9B-4535-A39F-CE1B6B44C796Q37427298-7C086FAB-48F6-4E2A-9129-C98A61F9A16DQ37577162-388F0A8B-15D4-42D4-A092-87225948A045Q37750278-1B0BA61E-CC14-4FFB-8AD2-BDA76230159CQ37949599-31F37D04-8505-460A-B03A-C5F4ABBCC602Q38524435-4C86951C-CAEE-4ED8-A7ED-B573CF844BADQ38832879-299B811A-8B30-49FA-ADFC-ADC55C56B7AEQ38925481-166B4F6F-196D-4D92-B5CE-1A55AB37EE61Q38951175-1B7CAA65-0B18-440B-ABF0-B4E1A48AAF9CQ39255963-A57067FC-1AB5-49C1-B909-52D0D1187F32Q39450184-5E901BAE-3D23-48BD-85E0-F841A492B6D8Q39480085-521006F4-A3A4-4F99-BA0B-505AADD00DD5
P2860
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Role of hyperglucagonemia in m ...... e output in type II diabetics.
@en
Role of hyperglucagonemia in m ...... e output in type II diabetics.
@nl
type
label
Role of hyperglucagonemia in m ...... e output in type II diabetics.
@en
Role of hyperglucagonemia in m ...... e output in type II diabetics.
@nl
prefLabel
Role of hyperglucagonemia in m ...... e output in type II diabetics.
@en
Role of hyperglucagonemia in m ...... e output in type II diabetics.
@nl
P2093
P356
P1433
P1476
Role of hyperglucagonemia in m ...... e output in type II diabetics.
@en
P2093
Kolterman OG
Schaeffer L
P304
P356
10.2337/DIAB.36.3.274
P407
P577
1987-03-01T00:00:00Z